Durrant addressed what he deemed as two key questions, regarding the sustainability of lenzilumab's market, as well as how competitively lenz was placed in the market.
Looking at product placement first, I see that NIH guidelines now recommend toci being considered to treat patients with >75mg/L CRP, when it was earlier to be considered for patients with >150mg/L of CRP. I don't know what justification there was for that change. But I assume toci's Hazard Ratio is still 1.44, well below our lowest HR, even before the updated study of our data. So we'll see if our updated HR of between 3.04 - 3.43 causes the NIH to reconsider their guidelines after our CRP biomarker peer-review is published. But as it stands, toci has encroached on our position to treat hospitalized and hypoxic patients.
To Durrant's second key question, in terms of the 1M additional Covid patients expected to be hospitalized in the US in 2022, why worry about distinguishing those with <150mg/L of CRP; then why consider only half of those patients, and then half again, to determine a sustainable market of 120K for lenz, just in the US, and, even much more so, why consider the need for lenz as an essential counter-measure for government stockpiling, and mention the revenue potential of billions of dollars, all of which requires the MOST essential element of our market sustainability, which is sufficient inventory of our product? Indeed, as Durrant said, this issue has not been talked about in much detail, so far.
Need it be, for us to consider? Or are we capable of determining what is needed in order to generate those billions in revenue?
I don't recall one word about overseas opportunity, either.
I think this management team, with this product, has accomplished the task of raising Humanigen from a micro-cap biotech, to the providers of a new blockbuster drug into the market.
There are some hints that could be given, to alleviate the financial pressure on share price. We could talk about receiving stockpiling purchase orders, as other companies have done, even in front of an EUA. Or we could announce our partnerships, which will enable us to meet demand, and remove that restriction from our constraints, as it appeared to me that Durrant did in his presentation. This is especially true if Clinigen and Cenexi have advanced our European commercialization efforts.
News 
Market Data 
Discover 
AI
